United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2016-2021, the global market is projected to touch US $89.19 billion.
Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection and screening.
Major driving factors for the market are streamlined drug delivery process, noninvasive technology, increased rates of survival. Increase boost in government and private funding for oncology also fuels the market growth. Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field.
United States biomarkers market is segmented based on type of applications, By service. United states Cancer Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic market.
Some of the major players in this market are Biomoda, Inc, Clarient, Inc, Ambrilia Biopharma,Diadexus, Inc, Affymetrix, Inc and Aureon Laboratories, Inc.
What makes our report Unique?
1) A wide and in depth analysis of various applications, and services provided in Global Biomarker market as well as cancer biomarker market.
2) We provide longest possible market segmentation based on the type of cancers, applications of biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services( Sample preparation, Assay development, biomarkers validation and testing)
3) We provide you a complete competitive landscape which includes major players in the market, mergers and acquisitions, Collaborations and new product launches.